naltrexone has been researched along with scopolamine hydrobromide in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (26.09) | 18.7374 |
| 1990's | 6 (26.09) | 18.2507 |
| 2000's | 9 (39.13) | 29.6817 |
| 2010's | 2 (8.70) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Adkison, KK; Humphreys, JE; Mahar Doan, KM; Polli, JW; Serabjit-Singh, CJ; Shampine, LJ; Webster, LO; Wring, SA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bilsky, EJ; Marglin, SH; Reid, LD | 1 |
| Hamm, RJ; Knisely, JS | 2 |
| Mayer, DJ; Watkins, LR | 1 |
| Chinn, C; Horita, A; Yabase, M | 1 |
| Cherkin, A; Flood, JF; Morley, JE | 1 |
| Cannon, JT; Lewis, JW; Liebeskind, JC | 1 |
| Itoh, J; Kameyama, T; Ukai, M | 1 |
| Itoh, J; Kameyama, T; Kobayashi, T; Shinkai, N; Ukai, M | 1 |
| Bymaster, FP; Mitch, CH; Olesen, PH; Sauerberg, P; Shannon, HE; Sheardown, MJ; Suzdak, PD; Swedberg, MD; Ward, JS | 1 |
| Kameyama, T; Shinkai, N; Ukai, M | 1 |
| Hiramatsu, M; Inoue, K | 1 |
| Xu, K; Yang, G; Zhou, W | 1 |
| Katoh, T; Mamiya, T; Ukai, M | 1 |
| Koseki, M; Matsumura, E; Sakaguchi, M; Wakamatsu, M | 2 |
| Hiramatsu, M; Hoshino, T | 1 |
2 review(s) available for naltrexone and scopolamine hydrobromide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Multiple endogenous opiate and non-opiate analgesia systems: evidence of their existence and clinical implications.
Topics: Acupuncture Therapy; Analgesia; Animals; Cholecystokinin; Conditioning, Classical; Desipramine; Dimethyl Sulfoxide; Drug Interactions; Electroshock; Endorphins; Enkephalin, Leucine; Mecamylamine; Morphine; N-Methylscopolamine; Naloxone; Naltrexone; Norepinephrine; Proglumide; Rats; Receptors, Cell Surface; Receptors, Cholecystokinin; Scopolamine; Scopolamine Derivatives; Serotonin; Spinal Cord | 1986 |
21 other study(ies) available for naltrexone and scopolamine hydrobromide
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barrier; Cell Line; Cell Membrane Permeability; Central Nervous System Agents; Dogs; Drug Delivery Systems; Permeability; Pharmaceutical Preparations | 2002 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Using antagonists to assess neurochemical coding of a drug's ability to establish a conditioned place preference.
Topics: Analgesics; Animals; Brain Chemistry; Conditioning, Operant; Flumazenil; Habituation, Psychophysiologic; Male; Morphine; Naloxone; Naltrexone; Rats; Rats, Inbred Strains; Scopolamine | 1990 |
Environmentally induced analgesia: ontogeny of a nonopioid system.
Topics: Analgesia; Animals; Cholinergic Fibers; Electroshock; Environment; Male; Naltrexone; Nervous System; Pain; Rats; Rats, Inbred Strains; Receptors, Opioid; Scopolamine | 1986 |
Clonidine activates a cholinergic hippocampal theta rhythm in the rat.
Topics: Animals; Clonidine; Electroencephalography; Hippocampus; Male; Morphine; Naltrexone; Rats; Rats, Inbred Strains; Reference Values; Scopolamine; Theta Rhythm; Yohimbine | 1988 |
Environmentally induced analgesia: age-related decline in a neurally mediated, nonopioid system.
Topics: Adrenalectomy; Aging; Analgesia; Animals; Male; Naltrexone; Rats; Rats, Inbred Strains; Receptors, Cholinergic; Scopolamine | 1986 |
Antagonism of endogenous opioids modulates memory processing.
Topics: Animals; Anisomycin; Avoidance Learning; Dose-Response Relationship, Drug; Electroshock; Endorphins; Learning; Male; Memory; Mice; Naloxone; Naltrexone; Scopolamine | 1987 |
Involvement of central muscarinic cholinergic mechanisms in opioid stress analgesia.
Topics: Animals; Electroshock; Endorphins; Male; Morphine; Naltrexone; Oxotremorine; Pain; Rats; Rats, Inbred Strains; Receptors, Cholinergic; Receptors, Muscarinic; Scopolamine; Stress, Physiological | 1983 |
Dynorphin A-(1-13) markedly improves scopolamine-induced impairment of spontaneous alternation performance in mice.
Topics: Analysis of Variance; Animals; Drug Interactions; Dynorphins; Male; Memory; Mice; Naltrexone; Peptide Fragments; Psychomotor Performance; Receptors, Opioid, kappa; Scopolamine | 1993 |
Effects of the kappa-opioid dynorphin A(1-13) on learning and memory in mice.
Topics: Analgesics, Opioid; Animals; Dynorphins; Injections, Intraventricular; Learning; Learning Disabilities; Male; Memory; Memory Disorders; Memory, Short-Term; Mice; Mice, Inbred Strains; Muscarinic Antagonists; Naltrexone; Narcotic Antagonists; Peptide Fragments; Pirenzepine; Receptors, Opioid, kappa; Scopolamine | 1997 |
M1 receptor agonist activity is not a requirement for muscarinic antinociception.
Topics: Analgesics; Animals; Atrial Function; Cell Line; Cricetinae; Guinea Pigs; Heart Atria; Humans; Hydrolysis; In Vitro Techniques; Inositol Phosphates; Male; Mice; Muscarinic Agonists; Muscle Contraction; N-Methylscopolamine; Naltrexone; Rabbits; Rats; Rats, Wistar; Receptor, Muscarinic M1; Receptors, Muscarinic; Scopolamine; Scopolamine Derivatives; Transfection; Vas Deferens | 1997 |
Ameliorative effects of tachykinins on scopolamine-induced impairment of spontaneous alternation performance in mice.
Topics: Animals; Male; Mice; Muscarinic Antagonists; Naloxone; Naltrexone; Narcotic Antagonists; Neurokinin A; Peptide Fragments; Psychomotor Performance; Scopolamine; Substance P; Tachykinins | 1998 |
Improvement by low doses of nociceptin on scopolamine-induced impairment of learning and/or memory.
Topics: Analgesics, Opioid; Animals; Avoidance Learning; Disease Models, Animal; Dizocilpine Maleate; Learning Disabilities; Male; Maze Learning; Memory Disorders; Mice; Naloxone; Naltrexone; Narcotic Antagonists; Neuroprotective Agents; Nociceptin; Opioid Peptides; Psychomotor Performance; Rats; Scopolamine | 2000 |
[The combined use of scopolamine, naltrexone and naloxone as a rapid, safe and effective detoxification treatment for heroin addicts].
Topics: Adult; Drug Therapy, Combination; Female; Follow-Up Studies; Heroin Dependence; Humans; Male; Naloxone; Naltrexone; Narcotic Antagonists; Scopolamine | 1999 |
Endomorphin-1 improves scopolamine-induced impairment of short-term memory via mu1-opioid receptor in mice.
Topics: Analgesics, Opioid; Animals; Brain; Dose-Response Relationship, Drug; Drug Interactions; Male; Maze Learning; Memory Disorders; Memory, Short-Term; Mice; Muscarinic Antagonists; Naloxone; Naltrexone; Narcotic Antagonists; Neurons; Oligopeptides; Receptors, Opioid, mu; Scopolamine | 2001 |
Effects of beta-casomorphin-5 on passive avoidance response in mice.
Topics: Analgesics; Animals; Avoidance Learning; Cerebral Ventricles; Endorphins; Injections, Intraventricular; Male; Mice; Mice, Inbred Strains; Naltrexone; Narcotic Antagonists; Peptide Fragments; Reaction Time; Scopolamine | 2003 |
Improvement of memory impairment by (+)- and (-)-pentazocine via sigma, but not kappa opioid receptors.
Topics: Acetic Acid; Analgesics, Opioid; Analysis of Variance; Animals; Anisoles; Antipsychotic Agents; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Exploratory Behavior; Isomerism; Male; Maze Learning; Memory Disorders; Mice; Naltrexone; Narcotic Antagonists; Pain Measurement; Pentazocine; Propylamines; Receptors, Opioid, kappa; Receptors, sigma; Scopolamine | 2005 |
Effects of systemic administration of beta-casomorphin-5 on learning and memory in mice.
Topics: Analgesics; Animals; Avoidance Learning; Cattle; Dose-Response Relationship, Drug; Endorphins; Injections, Intraperitoneal; Injections, Intraventricular; Injections, Subcutaneous; Male; Memory; Mice; Naloxone; Naltrexone; Narcotic Antagonists; Peptide Fragments; Receptors, Opioid, mu; Scopolamine | 2006 |